Abbott Has Selected Two Additional Cancer Targets From Celera Genomics For Further Development
Seven Celera Genomics Antigens Now in Research Pipeline with Partners
Under the terms of the collaboration agreement, a number of protein antigens identified and validated by Celera Genomics are being screened by Abbott. The collaboration encompasses the development of therapeutic antibodies and small molecule drugs against over-expressed cell-surface proteins that have been associated with cancer and identified as therapeutic targets through proteomics research at Celera Genomics. Any of these antigens may be selected for therapeutic development at Abbott. Once this development is complete, Celera Genomics may elect to jointly fund clinical development and commercialization of any resulting therapeutic products and would share any financial returns resulting from commercialization, or alternately be paid milestones and royalties on successful therapies. Abbott has responsibility for the commercialization of jointly funded collaboration products. Celera Genomics retains certain diagnostic rights associated with selected targets.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous